BRIEF published on 02/20/2026 at 07:05, 4 months 7 days ago BB Biotech AG Releases 2025 Annual Report Dividend Proposal Biotechnology Sector Net Profit Increase BB Biotech 2025 Annual Report
BRIEF published on 02/20/2026 at 07:05, 4 months 7 days ago BB Biotech's 2025 Annual Report Highlights Strong Financial Gains Annual Report Portfolio Value Shareholder Returns BB Biotech Financial Gains
BRIEF published on 02/20/2026 at 07:05, 4 months 7 days ago Le rapport annuel 2025 de BB Biotech met en lumière d'importants résultats financiers. Rapport Annuel BB Biotech Valeur Du Portefeuille Rendements Pour Les Actionnaires Gains Financiers
PRESS RELEASE published on 02/20/2026 at 07:00, 4 months 7 days ago EQS-Adhoc: BB Biotech AG publishes its 2025 annual report BB Biotech AG releases its 2025 annual report, reporting a strong performance with a +34.2% total return in CHF. The annual report includes detailed information on the biotechnology sector and the company's investments Financial Results Investment BB Biotech AG Biotechnology Sector 2025 Annual Report
PRESS RELEASE published on 02/20/2026 at 07:00, 4 months 7 days ago Annual Report 2025: BB Biotech delivers strong performance and portfolio value realization BB Biotech AG's Annual Report 2025 showcases strong performance and portfolio value realization. Shareholder returns, active capital management, and refined investment processes highlighted BB Biotech AG Portfolio Value Shareholder Returns Annual Report 2025 Investment Processes
BRIEF published on 01/23/2026 at 07:05, 5 months 4 days ago BB Biotech AG Reports Significant Profit for 2025 Investment Company BB Biotech AG Drug Developers 2025 Profit Share Price Development
BRIEF published on 01/23/2026 at 07:05, 5 months 4 days ago BB Biotech AG annonce des bénéfices importants pour 2025 BB Biotech AG Société D'investissement Développeurs De Médicaments Bénéfices 2025 Évolution Du Cours De L'action
BRIEF published on 01/23/2026 at 07:05, 5 months 4 days ago BB Biotech Reports Strong Preliminary 2025 Results and Dividend Proposal Dividend Proposal Share Performance BB Biotech Biotech Investment 2025 Financial Results
BRIEF published on 01/23/2026 at 07:05, 5 months 4 days ago BB Biotech annonce des résultats préliminaires solides pour 2025 et une proposition de dividende Proposition De Dividende BB Biotech Performance Des Actions Résultats Financiers 2025 Investissement En Biotechnologie
PRESS RELEASE published on 01/23/2026 at 07:00, 5 months 4 days ago EQS-Adhoc: BB Biotech AG closes the 2025 fiscal year with a profit BB Biotech AG closes the 2025 fiscal year with a profit of approximately CHF 578 million, reflecting share price development. Full report on Feb 20, 2026 BB Biotech AG Profit 2025 Fiscal Year Share Price Development CHF 578 Million
Published on 06/27/2026 at 01:40, 6 hours 53 minutes ago Polaris Renewable Energy Announces Results of Director Elections at Annual and Special Meeting
Published on 06/27/2026 at 00:00, 8 hours 33 minutes ago Onco-Innovations Initiates Three-Species Hepatocyte and Microsome Metabolism Studies for ONC010
Published on 06/26/2026 at 23:00, 9 hours 33 minutes ago Canadian North Resources Inc. Announces Results of 2026 Annual General and Special Shareholders Meeting
Published on 06/26/2026 at 22:50, 9 hours 43 minutes ago Banyan Gold Files Technical Report for AurMac Project, Yukon, Canada
Published on 06/26/2026 at 22:15, 10 hours 18 minutes ago Revive Therapeutics Announces Proposed Private Placement
Published on 06/27/2026 at 00:05, 8 hours 27 minutes ago EAN Congress: Hearing aid use linked to 23% lower dementia risk in people with both epilepsy and hearing loss
Published on 06/27/2026 at 00:04, 8 hours 28 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent - Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 8 hours 57 minutes ago Persistent and Nagarro sign Business Combination Agreement to form the Persistent – Nagarro Group, a global leader in AI-led digital engineering
Published on 06/26/2026 at 23:36, 8 hours 57 minutes ago EQS-Adhoc: Nagarro SE: Nagarro signs business combination agreement with Persistent Systems and supports voluntary public takeover offer to all shareholders at EUR 81 per share
Published on 06/26/2026 at 23:27, 9 hours 5 minutes ago EQS-WpÜG: Takeover Offer / Target company: Nagarro SE; Bidder: Galaxy Germany Holding SE
Published on 06/26/2026 at 17:45, 14 hours 48 minutes ago Descriptif du programme de rachat d'actions
